HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market Feb 10, 2022
Therapsil CEO Spencer Hawkswell Speaks To Health Canada’s Intent To Deny Section 56 Exemptions To Healthcare… Feb 9, 2022
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of… Feb 9, 2022
